Stockreport

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Dostarlimab-gxly plus chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival (OS) in the overa [Read more]